Author:
Tarao Kazuo,Tanaka Katsuaki,Nozaki Akito,Sato Akira,Ishii Toshiya,Komatsu Hirokazu,Ikeda Takaaki,Komatsu Tatsuji,Matsushima Shozo,Oshige Kenji
Publisher
Baishideng Publishing Group Inc.
Reference29 articles.
1. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders
2. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
3. Chayama K, Suzuki Y, Ikeda K, Toyota J, Karino Y, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N. All-oral combination of daclatasvir plus asunaprevir in interferon ineligible naive/intolerant and nonresponder Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 trial. The 64th Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC, November 1-5, 2013. Available from: http://www.hivandmore.de/kongresse/aasld2013/HCV_DAA_AASLD2013_AI447-026_Japan_DUAL_Ph3_Chayama_Oral_nr211.pdf.
4. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
5. Kurosaki M. Treatment strategy for eldery patients with chronic hepatitis C. Igakunoayumi 2014;249:247-252.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献